SNAP-8
An 8 amino acid peptide analog of SNAP-25. Studied as a topical anti-wrinkle compound that reduces muscle contraction at the neuromuscular junction site.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How SNAP-8 Works
SNAP-8 (Acetyl Octapeptide-3) is an 8-amino acid synthetic peptide that extends its parent compound Argireline by two amino acids for improved efficacy. It mimics the N-terminus of SNAP-25, a key protein in the SNARE complex responsible for synaptic vesicle fusion. Both SNAP-8 and botulinum toxin target SNAP-25, but BOTOX breaks it (causing paralysis) while SNAP-8 captures it (causing relaxation).
- Competes with endogenous SNAP-25 for ternary complex binding
- Destabilizes SNARE assembly required for vesicle docking
- Reduces acetylcholine exocytosis at motor endplates
- Attenuates repetitive muscle microcontraction intensity
- Targets periorbital (crow's feet) and perioral expression lines
- Graded relaxation vs. complete paralysis (BOTOX distinction)
- Reduced mechanical stress allows collagen remodeling
- Enhanced efficacy demonstrated with microneedle patch delivery
- Synergizes with retinoid and antioxidant regimens
SNAP-8 competes with native SNAP-25 for SNARE complex assembly (SNAP-25/VAMP/Syntaxin) at presynaptic terminals. By capturing SNAP-25, it prevents ternary complex formation required for vesicle docking and neurotransmitter exocytosis, reducing acetylcholine release to produce graded muscle relaxation without paralysis.
J Anal Sci Technol (2020): Acetyl octapeptide-3 is more effective than acetyl hexapeptide-3 for wrinkle relief.
Preclinical Findings
Research Models
Clinical Data
Up to 63% Wrinkle Reduction — 30% More Active Than Argireline
Clinical studies reported up to 63.13% reduction in periorbital wrinkle severity at optimal treatment duration. A multicenter randomized placebo-controlled trial of the parent compound Argireline showed 48.9% total anti-wrinkle efficiency vs. 0% placebo (P<0.01). SNAP-8 is approximately 30% more active than Argireline per manufacturer in vivo/in vitro testing. An open-label trial in J Drugs Dermatol (2016) showed statistically significant improvement in facial lines and wrinkles at week 14.
J Drugs Dermatol (2016); J Anal Sci Technol (2020); Multicenter Argireline RCT (Chinese subjects).
Open-label clinical trial; multicenter placebo-controlled RCT; manufacturer studies
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Topical peptide — no systemic adverse effects reported in clinical studies
- Non-paralytic mechanism (muscle relaxation vs. botulinum toxin paralysis)
- No irritation, sensitization, or phototoxicity in dermatological patch testing
- Efficacy is formulation-dependent: pH, concentration (5–10%), and penetration enhancers are critical
- Real-world results (10–30% reduction) may be more modest than maximum clinical claims (63%)
SNAP-8 clinical data is primarily from manufacturer-funded studies. Independent large-scale trials are limited. Results vary significantly by formulation quality. For research use only.
About SNAP-8
An 8 amino acid peptide analog of SNAP-25. Studied as a topical anti-wrinkle compound that reduces muscle contraction at the neuromuscular junction site.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
